izpis_h1_title_alt

Identification of plasma biomarker candidates in glioblastoma using an antibody-array-based proteomic approach
Zupančič, Klemen (Avtor), Blejec, Andrej (Avtor), Herman, Ana (Avtor), Veber, Matija (Avtor), Verbovšek, Urška (Avtor), Koršič, Marjan (Avtor), Knežević, Miomir (Avtor), Rožman, Primož (Avtor), Lah Turnšek, Tamara (Avtor), Gruden, Kristina (Avtor), Motaln, Helena (Avtor)

URLURL - Predstavitvena datoteka, za dostop obiščite http://www.degruyter.com/view/j/raon.2014.48.issue-3/raon-2014-0014/raon-2014-0014.xml?format=INT Novo okno

Izvleček
Background. Glioblastoma multiforme (GBM) is a brain tumour with a very high patient mortality rate, with a median survival of 47 weeks. This might be improved by the identification of novel diagnostic, prognostic and predictive therapy-response biomarkers, preferentially through the monitoring of the patient blood. The aim of this study was to define the impact of GBM in terms of alterations of the plasma protein levels in these patients. Materials and methods. We used a commercially available antibody array that includes 656 antibodies to analyse blood plasma samples from 17 healthy volunteers in comparison with 17 blood plasma samples from patients with GBM. Results. We identified 11 plasma proteins that are statistically most strongly associated with the presence of GBM. These proteins belong to three functional signalling pathways: T-cell signalling and immune responses; cell adhesion and migration; and cell-cycle control and apoptosis. Thus, we can consider this identified set of proteins as potential diagnostic biomarker candidates for GBM. In addition, a set of 16 plasma proteins were significantly associated with the overall survival of these patients with GBM. Guanine nucleotide binding protein alpha (GNAO1) was associated with both GBM presence and survival of patients with GBM. Conclusions. Antibody array analysis represents a useful tool for the screening of plasma samples for potential cancer biomarker candidates in small-scale exploratory experiments; however, clinical validation of these candidates requires their further evaluation in a larger study on an independent cohort of patients.

Jezik:Angleški jezik
Ključne besede:glioblastoma, proteomics, biomarker
Vrsta gradiva:Delo ni kategorizirano (r6)
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:MF - Medicinska fakulteta
Leto izida:2014
Št. strani:str. 257-266, III
Številčenje:Vol. 48, no. 3
UDK:616.831-006-07
ISSN pri članku:1318-2099
DOI:10.2478/raon-2014-0014 Povezava se odpre v novem oknu
COBISS.SI-ID:31525081 Povezava se odpre v novem oknu
Število ogledov:354
Število prenosov:247
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
 
Skupna ocena:(0 glasov)
Vaša ocena:Ocenjevanje je dovoljeno samo prijavljenim uporabnikom.
:
Objavi na: Bookmark and Share

Gradivo je del revije

Naslov:Radiology and oncology
Skrajšan naslov:Radiol. oncol.
Založnik:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 Novo okno

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:glioblastom, proteomika, biomarker

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Komentarji

Dodaj komentar

Za komentiranje se morate prijaviti.

Komentarji (0)
0 - 0 / 0
 
Ni komentarjev!

Nazaj